A new clinical research trial has launched in Kazakhstan to evaluate whether an artificial intelligence model can analyze standard electrocardiograms (ECGs) and detect subtle markers of heart failure. The primary goal is assessing whether the algorithm can reliably assist primary care physicians in determining when to prioritize a patient for advanced cardiac screening.
The system does not establish a definitive clinical diagnosis: that responsibility remains strictly with medical specialists based on comprehensive examinations. However, if validated, the model could help outpatient clinics triage patients who urgently need echocardiography or cardiologist consultations.
What the Project Aims to Detect
In heart failure, the cardiac muscle struggles to pump blood efficiently throughout the body. Patients frequently experience shortness of breath under ordinary physical exertion, severe chronic fatigue, or fluid retention in the lower extremities.
Underlying etiologies typically include ischemic heart disease and sustained hypertension. To establish a diagnosis, clinicians utilize multiple diagnostic pathways: electrocardiograms, biomarker blood tests, echocardiograms, and additional specialized imaging. Consequently, an isolated ECG trace does not provide an exhaustive clinical picture.
The Kazakhstani initiative is designed to intervene at the initial triage stage: identifying which asymptomatic or ambiguous patients warrant urgent downstream investigation.
How the Diagnostic Pipeline Operates
An ECG captures the electrical conduction activity of the heart. During standard non-invasive testing, surface electrodes placed on the patient’s skin register cardiac depolarization signals.
Under the new workflow, these raw digitized waveforms will be evaluated by an AI model. Its function is to assist physicians in selecting candidates for echocardiography (EchoCG). Designed primarily for outpatient polyclinics, ultimate diagnostic decisions rest entirely with medical practitioners.
Echocardiography is cardiac ultrasound imaging that reveals anatomical structural integrity and evaluates functional pumping dynamics, supplying essential clinical context that standard electrical recordings cannot offer.
The projected clinical scenario proceeds as follows: a patient undergoes routine ECG, the neural network flags hidden statistical risk, the physician synthesizes this finding with patient history and symptoms, and determines whether an immediate echocardiogram referral is warranted.
Project Stakeholders and Technological Footprint
The collaborative project brings together the Ministry of Health of the Republic of Kazakhstan, the Kazakh Society of Heart Failure Specialists, and CMC Technologies, supported by AstraZeneca Kazakhstan. Cardiologists provide clinical oversight, while CMC Technologies supplies the software infrastructure.
CMC Technologies has operated a nationwide remote ECG diagnostic infrastructure since 2019. According to Health Ministry statistics, the platform has processed over four million diagnostic recordings, interconnecting over 140 medical institutions and 400 regional clinical branches.
The four million figure reflects historical volume across the legacy ECG telemetry network. It does not measure validations completed by the new AI algorithm, nor does it confirm algorithmic diagnostic accuracy.
What Clinical Trials Are Currently Measuring
The model was trained on anonymized historical cardiac datasets. Current trials will cross-reference predictive AI outputs against confirmed echocardiography findings. Based on these comparisons, researchers will quantify diagnostic specificity, sensitivity, and clinical deployment viability.
Practical clinical utility hinges on two core metrics: the false negative rate (how often the model fails to detect impaired cardiac function) and the false positive rate (how often it flags healthy individuals, overburdening ultrasound facilities).
False negatives risk delaying crucial therapy, while excess false positives overburden scarce diagnostic equipment and specialist queues. Evaluating this tool requires measuring how effectively it optimizes the patient trajectory from raw ECG screening to definitive clinical resolution.
Timeline for Polyclinic Integration
Project documentation outlines two implementation phases. The preliminary phase focuses on retrospective clinical data analysis and patient referral modeling. Pilot deployment of the AI module within active outpatient polyclinics is slated to commence in 2027.
Present activities represent early-stage scientific validation. There is currently no evidence supporting claims that the technology is ready for population-wide clinical care or that it has provenly reduced hospitalization rates.
Should clinical validation confirm reliability, standard electrocardiograms could offer primary care doctors an invaluable early-warning indicator. For patients, this creates an opportunity for prompt referrals and early intervention before heart failure progresses to irreversible stages.
